#Japan #Digital Transformation #Tokyo #Astellas Pharma #Naoki Okamura

Astellas Pharma Restructures Top Management

On September 29, 2025, Astellas Pharma Inc., a global leader in the biopharmaceutical industry, disclosed significant changes in its top management following the departure of its Chief Digital Transformation Officer (CDTO), Nick Eshkenazi. Transitioning into a new era, the company aims to integrate key functions into a more strategically aligned structure. The adjustments are set to take effect on October 1, 2025, marking a substantial shift in how the company will tackle future challenges and opportunities.

Under the leadership of President and CEO Naoki Okamura, Astellas is recommitting its focus to aligning digital capabilities with strategic initiatives. The CDTO position, held by Eshkenazi until September 30, 2025, will be dissolved. All responsibilities related to digital transformation and other functions will now be absorbed by the strategy department, overseen by Adam Pearson, the newly designated Chief Strategy Officer. This transition reflects Astellas' commitment to enhancing its strategic direction, especially in an ever-evolving healthcare landscape.

As of October 1, 2025, the top management team will consist of:

• - Naoki Okamura - Representative Director, President and CEO
• - Katsuyoshi Sugita - Representative Director, Corporate Executive Vice President, Chief People Officer
• - Tadaaki Taniguchi - Chief Research Development Officer
• - Rao Mantri - Chief Manufacturing Officer
• - Claus Zieler - Chief Commercial Medical Affairs Officer
• - Adam Pearson - Chief Strategy Officer
• - Atsushi Kitamura - Chief Financial Officer
• - Tatjana Dragovic - General Counsel and Chief Ethics Compliance Officer

This strategic restructuring is not merely a change in titles but aims to reflect Astellas' deep commitment to innovation and the development of transformative therapies for patients. The company is renowned for its cutting-edge solutions in various therapeutic areas, including oncology and immunology. By deeply integrating digital strategies into its core operations, Astellas seeks to position itself in line with contemporary demands in drug development and market accessibility.

Looking ahead, Astellas is poised to prioritize initiatives that enhance its research and development programs, addressing unmet medical needs through innovative solutions. In doing so, Astellas aspires to forge a stronger healthcare future, leading efforts to create value for patients across the globe.

In addition to its recent management changes, Astellas continues to emphasize the importance of adhering to high standards of ethical conduct and compliance, ensuring that its strategies align with rigorous regulatory requirements and best practices. As it continues to navigate the complexities of the biopharmaceutical landscape, Astellas reaffirms its commitment to pioneering healthcare advancements, delivering on its promise to turn innovative science into tangible value for patients.

Astellas Pharma is dedicated to transforming scientific breakthroughs into therapies that significantly improve patients' lives. Prospective investors and interested stakeholders are encouraged to keep abreast of potential developments and forthcoming announcements from the company during this pivotal transition phase.

For more information on Astellas, visit www.astellas.com.

Cautionary Notes: The statements made in this announcement regarding future plans, estimates, and strategies constitute forward-looking statements, reflecting management's current beliefs. It is important to acknowledge that various factors could cause actual results to differ from these projections, including changes in economic conditions and regulatory environments. The company does not make any guarantees regarding these statements and urges stakeholders to consider potential risks associated with their investments.